UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
March 23, 2022
__________________
Commission File Number: 001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form 20-F | ☒ |
Form 40-F | ☐ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On March 23, 2022, Immatics N.V. (the “Company”) issued a press release announcing its full year 2021 financial results and providing certain corporate updates. A copy of the press release is attached hereto as Exhibit 99.1. In addition, the Company made available an updated investor presentation. A copy of the presentation is attached hereto as Exhibit 99.2. The fact that the presentation is being made available and furnished herewith is not an admission as to the materiality of any information contained in the presentations. The information contained in the presentation is being provided as of March 23, 2022 and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results.
EXHIBIT INDEX
| Exhibit No. | Description |
| 99.1 | Press release dated March 23, 2022 |
| 99.2 | Corporate presentation dated March 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMMATICS N.V. | ||
| Date: March 23, 2022 | ||
| By: | /s/ Harpreet Singh | |
| Name: | Harpreet Singh | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
PRESS RELEASE
Immatics Announces Full Year 2021 Financial
Results
and Corporate Update
| · | IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation |
| · | Multiple IMA203 Phase 1b expansion cohorts being initiated in Q2 2022 including monotherapy at target dose level, checkpoint combination therapy, and 2nd-generation approach IMA203CD8 |
| · | Immatics entered a global licensing agreement with Bristol Myers Squibb to collaborate on clinical development of TCR Bispecific (TCER®) IMA401 targeting MAGEA4/A8; agreement includes $150million upfront payment, up to $770 million in milestone payments, tiered double-digit royalties and a co-promotion option in the U.S. |
| · | TCER® IMA401 IND1 approved by regulatory authorities in February 2022; initiation of patient treatment in the first half of 2022 |
| · | TCER® IMA402 targeting PRAME demonstrated preclinical proof-of-concept and initial steps towards GMP manufacturing have been initiated |
| · | Nancy Valente appointed to Immatics’ Board of Directors |
| · | Cash and cash equivalents as well as Other financial assets amount to $164 million2 (€145 million) as of December 31, 2021. Addition of upfront payment from the recent collaboration agreement with Bristol Myers Squibb received in February 2022 ensures cash runway into 2024 |
Tuebingen, Germany and Houston, TX, March 23, 2022 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2021.
Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics commented, “Over the course of 2021, Immatics has continued to deliver important milestones across both our clinical and preclinical portfolio. Our Phase 1a data presentation at SITC demonstrated high initial objective response rates in solid cancer patients treated with our ACTengine® IMA203 TCR-T candidate, and we have achieved preclinical proof-of-concept for our TCR Bispecific candidate, TCER® IMA402 – both targeting PRAME, a target frequently expressed on multiple solid cancers. We have also expanded our collaboration with Bristol Myers Squibb to jointly develop our TCER® IMA401 targeting MAGEA4 and MAGEA8 and we plan to initiate the first-in-man clinical trial of IMA401 in the first half of 2022. Together with the company’s strong cash position and further potential opportunities to create valuable partnerships based on our differentiated TCR-based platforms, we are very well positioned to deliver on all relevant upcoming value inflections points across our cell therapy and bispecifics portfolio.”
1 Clinical Trial Application (CTA) approved, the equivalent of an Investigational New Drug (IND) application in Europe
2 All amounts translated using the exchange rate published by the European Central Bank in effect as of December 31, 2021 (1 EUR = 1.1326 USD)
| Immatics Press Release March 23, 2022 | 1 | 10 |
Fourth Quarter 2021 and Subsequent Company Progress
Adoptive Cell Therapy Programs
| · | ACTengine® IMA203 (PRAME) - Immatics provided an interim update on its most advanced Phase 1a TCR-T trial with IMA203 targeting PRAME in a late-breaking oral presentation by Dr. Martin Wermke, coordinating investigator of the trial, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2021. Objective responses (confirmed and unconfirmed partial responses, RECIST 1.1) were observed in 8 out of 16 patients (50%), and 8 out of 13 patients (62%) who were treated at intermediate dose levels 2 and 3 in the dose escalation part of the trial. Objective responses were associated with tumor infiltration and peak T cell persistence in the blood. Treatment-emergent events were transient and manageable; no grade 3 or higher cytokine release syndrome or neurological toxicities were observed. |
| · | Patient treatment in the Phase 1a study with IMA203 has been completed. Dose level 4 (up to 1.2 billion transduced T cells per m2) has been determined as the provisional Recommended Phase 2 Dose (RP2D). The next data read-out for IMA203 monotherapy is planned for 2H 2022. |
| · | Based on these interim results, Immatics is expanding the IMA203 study to three Phase 1b dose expansion cohorts, each designed to evaluate the observed objective response rate, demonstrate durability of response and provide the basis for entering registration trials. Cohorts include IMA203 as monotherapy in focus indications, IMA203 in combination with an immune checkpoint inhibitor and IMA203CD8, a 2nd generation monotherapy where IMA203 is co-transduced with a CD8 co-receptor, thereby inducing anti-tumor activity of both CD4 and CD8 T cells. These three Phase 1b IMA203 expansion cohorts are being initiated in Q2 2022. An initial data read-out for the IMA203/immune checkpoint inhibitor combination therapy cohort and the IMA203CD8 cohort is planned for YE2022. |
| · | ACTengine® IMA201 (MAGEA4/8) and IMA202 (MAGEA1) – In November 2021, Immatics presented interim data on 12 heavily pre-treated patients that were treated with product candidates IMA201 and IMA202. 8 out of 12 patients (67%) showed disease control, and tumor shrinkage was observed in 6 patients (50%). All adverse events for IMA201 and IMA202 were transient and manageable with no dose-limiting toxicities observed. For IMA202, patient recruitment in the dose escalation part of the Phase 1 trial has been completed. For IMA201, dose escalation is ongoing. |
| · | ACTengine® IMA204 (COL6A3 exon 6) – IMA204 is a first-in-class TCR-T directed against COL6A3 exon 6, a novel tumor stroma target highly expressed in several solid cancers. IMA204 utilizes a next-generation CD8-independent TCR with full functionality in both CD4 and CD8 T cells. IND-enabling studies are nearing completion. Submission of the IND application for IMA204 is expected by the end of 2022. |
| Immatics Press Release March 23, 2022 | 2 | 10 |
TCR Bispecifics Programs
| · | TCER® IMA401 (MAGEA4/8) – Immatics entered a global exclusive licensing deal with Bristol Myers Squibb for its most advanced TCER® product candidate, IMA401. The agreement included an upfront payment of $150 million as well as up to $770 million in additional milestone payments plus tiered double-digit royalties on net product sales, and includes the retention of the option to co-fund U.S. development in return for further enhanced U.S. royalties. Both companies will collaborate to advance the program through clinical development with Immatics retaining a co-promotion option in the U.S. In preclinical proof-of-concept studies, IMA401 demonstrated anti-tumor activity with complete remissions in different in vivo tumor models including patient-derived xenograft models. A clinical trial application (CTA, the equivalent of an IND in Europe) for the IMA401 program was filed in November 2021 with the Paul-Ehrlich-Institute, the relevant German regulatory authority and approved in February 2022. Start of the Phase 1 clinical trial is planned for the first half of 2022. |
| · | TCER® IMA402 (PRAME) – Immatics presented data from its second TCER® program IMA402 at the 17th Annual PEGS Boston Protein Engineering and Cell Therapy Summit in May 2021 demonstrating preclinical proof-of-concept for the program. IMA402 showed in vitro anti-tumor activity and consistent tumor regression including complete responses in an in vivo tumor model. Continuation of GMP process development and IND-enabling activities for IMA402 is anticipated in 2022. Manufacturing of the clinical batch is targeted for the second half of 2022 and initiation of the Phase 1 trial is planned in 2023. |
Corporate Developments
Board of Directors Update
| · | In March 2022, Nancy Valente, M.D., was appointed to the Immatics’ Board of Directors and will be nominated for election at the Company’s Annual General Meeting in June 2022. Nancy Valente brings to Immatics over 20 years of experience in oncology and hematology drug development. In her last position at Genentech/Roche, she was Senior Vice President, Oncology Product Development, where she helped to build a diverse portfolio of new oncology therapies encompassing small molecules, antibodies, bispecific antibodies and antibody drug conjugates including Gazyva®, Polivy®, Hemlibra® and Venclexta®, a first-to-market BCL-2 inhibitor. Additional information about Nancy Valente and the other members of Immatics’ Board of Directors can be found on the Immatics website. |
| · | In July 2021, Immatics adopted a one-tier structure for its Board of Directors. As part of this process, the company’s CEO Harpreet Singh, Ph.D., joined the Board. |
| · | In June 2021, Friedrich von Bohlen und Halbach, Ph.D., Managing Director of dievini Hopp BioTech Holding GmbH & Co. KG was elected to Immatics’ Board of Directors. Dr. von Bohlen und Halbach replaced Christof Hettich, L.L.D., who stepped down from the Board of Directors after 15 years of valuable service to the company. |
| Immatics Press Release March 23, 2022 | 3 | 10 |
Full Year 2021 Financial Results
Cash Position: Cash and cash equivalents as well as other financial assets total €145.1 million ($164.3 million2) as of December 31, 2021 compared to €232.0 million ($262.7 million2) as of December 31, 2020. The decrease is mainly the result of financing of our ongoing research and development activities. This does not include $150 million cash received in February 2022 from the collaboration agreement signed with Bristol Myers Squibb in December 2021. Adding this upfront payment, the Company projects a cash runway into 2024.
Revenue: Total revenue, consisting of revenue from collaboration agreements, was €34.8 million ($39.4 million2) for the year ended December 31, 2021, compared to €31.3 million ($35.4 million2) for the year ended December 31, 2020.
Research and Development Expenses: R&D expenses were €87.6 million ($99.2 million2) for the year ended December 31, 2021, compared to €67.1 million ($76.0 million2) for the year ended December 31, 2020. The increase mainly resulted from higher costs associated with the advancement of the clinical and pre-IND pipeline of candidates.
General and Administrative Expenses: G&A expenses were €33.8 million ($38.3 million2) for the year ended December 31, 2021, compared to €34.2 million ($38.7 million2) for the year ended December 31, 2020.
Net Loss: Net loss was €93.3 million ($105.7 million2) for the year ended December 31, 2021, compared to €211.8 million ($239.9 million2) for the year ended December 31, 2020. The decrease mainly resulted from a one-time, non-cash expense in connection with the ARYA merger in 2020 of €152.8 million ($173.0 million2).
Full financial statements can be found in the Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) and published on the SEC website under www.sec.gov.
Upcoming Investor Conferences
| · | Bank of America Healthcare Conference (in person) Las Vegas, NV – May 10-12, 2022 |
| · | Jefferies LLC Healthcare Conference (in-person) New York, NY – June 8-10, 2022 |
| · | Goldman Sachs Global Healthcare Conference, Rancho Palos Verdes, CA – June 14-16, 2022 |
| · | Jefferies LLC London Healthcare Conference, London, U.K. – November 15-17, 2022 |
To see the full list of events and presentations, visit www.investors.immatics.com/events-presentations.
2 All amounts translated using the exchange rate published by the European Central Bank in effect as of December 31, 2021 (1 EUR = 1.1326 USD).
| Immatics Press Release March 23, 2022 | 4 | 10 |
About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on Twitter, Instagram and LinkedIn.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics’ future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics’ focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the SEC. Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.
For more information, please contact:
| Media and Investor Relations Contact | |
| Jacob Verghese or Stephanie May | |
| Trophic Communications | |
| Phone: +49 89 2388 7731 | |
| immatics@trophic.eu |
| Immatics N.V. | |
| Anja Heuer | Jordan Silverstein |
| Director Corporate Communications | Head of Strategy |
| Phone: +49 89 540415-606 | Phone: +1 281 810 7545 |
| media@immatics.com | InvestorRelations@immatics.com |
| Immatics Press Release March 23, 2022 | 5 | 10 |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Financial Position of Immatics N.V.
As of | ||||||||
December 31, 2021 | December 31, 2020 | |||||||
| (Euros in thousands) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | 132,994 | 207,530 | ||||||
| Other financial assets | 12,123 | 24,448 | ||||||
| Accounts receivable | 682 | 1,250 | ||||||
| Other current assets | 6,408 | 5,763 | ||||||
| Total current assets | 152,207 | 238,991 | ||||||
| Non-current assets | ||||||||
| Property, plant and equipment | 10,506 | 7,868 | ||||||
| Intangible assets | 1,315 | 914 | ||||||
| Right-of-use assets | 9,982 | 6,149 | ||||||
| Other non-current assets | 636 | 724 | ||||||
| Total non-current assets | 22,439 | 15,655 | ||||||
| Total assets | 174,646 | 254,646 | ||||||
| Liabilities and shareholders’ equity | ||||||||
| Current liabilities | ||||||||
| Provisions | 51 | 51 | ||||||
| Accounts payable | 11,624 | 10,052 | ||||||
| Deferred revenue | 50,402 | 46,600 | ||||||
| Other financial liabilities | 27,859 | 16,869 | ||||||
| Lease liabilities | 2,711 | 1,881 | ||||||
| Other current liabilities | 2,501 | 2,025 | ||||||
| Total current liabilities | 95,148 | 77,478 | ||||||
| Non-current liabilities | ||||||||
| Deferred revenue | 48,225 | 85,475 | ||||||
| Lease liabilities | 7,142 | 4,306 | ||||||
| Other non-current liabilities | 68 | — | ||||||
| Total non-current liabilities | 55,435 | 89,781 | ||||||
| Shareholders’ equity | ||||||||
| Share capital | 629 | 629 | ||||||
| Share premium | 565,192 | 538,695 | ||||||
| Accumulated deficit | (537,813 | ) | (444,478 | ) | ||||
| Other reserves | (3,945 | ) | (7,459 | ) | ||||
| Total shareholders’ equity | 24,063 | 87,387 | ||||||
| Total liabilities and shareholders’ equity | 174,646 | 254,646 | ||||||
| Immatics Press Release March 23, 2022 | 6 | 10 |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Loss of Immatics N.V.
| Year ended December 31, | ||||||||||||
| 2021 | 2020 | 2019 | ||||||||||
| (Euros in thousands, except share and per share data) | ||||||||||||
| Revenue from collaboration agreements | 34,763 | 31,253 | 18,449 | |||||||||
| Research and development expenses | (87,574 | ) | (67,085 | ) | (40,091 | ) | ||||||
| General and administrative expenses | (33,808 | ) | (34,186 | ) | (11,756 | ) | ||||||
| Other income | 332 | 303 | 385 | |||||||||
| Operating result | (86,294 | ) | (69,715 | ) | (33,013 | ) | ||||||
| Financial income | 5,675 | 2,949 | 790 | |||||||||
| Financial expenses | (1,726 | ) | (10,063 | ) | (264 | ) | ||||||
| Change in fair value of warrant liabilities | (10,990 | ) | 17,775 | — | ||||||||
| Share listing expense | — | (152,787 | ) | — | ||||||||
| Financial result | (7,041 | ) | (142,126 | ) | 526 | |||||||
| Loss before taxes | (93,335 | ) | (211,841 | ) | (32,487 | ) | ||||||
| Taxes on income | — | — | — | |||||||||
| Net loss | (93,335 | ) | (211,841 | ) | (32,487 | ) | ||||||
| Attributable to: | ||||||||||||
| Equity holders of the parent | (93,335 | ) | (211,284 | ) | (31,571 | ) | ||||||
| Non-controlling interest | — | (557 | ) | (916 | ) | |||||||
| Net loss | (93,335 | ) | (211,841 | ) | (32,487 | ) | ||||||
| Net loss per share - basic and diluted | (1.48 | ) | (4.40 | ) | (0.95 | ) | ||||||
| Weighted average shares outstanding - basic and diluted | 62,912,921 | 48,001,228 | 33,093,838 | |||||||||
| Immatics Press Release March 23, 2022 | 7 | 10 |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Comprehensive Loss of Immatics N.V.
| Year ended December 31, | ||||||||||||
| 2021 | 2020 | 2019 | ||||||||||
| (Euros in thousands) | ||||||||||||
| Net Loss | (93,335 | ) | (211,841 | ) | (32,487 | ) | ||||||
| Other comprehensive loss | ||||||||||||
| Items that may be reclassified subsequently to profit or loss, net of tax | — | — | — | |||||||||
| Currency translation differences from foreign operations | 3,514 | (6,689 | ) | (29 | ) | |||||||
| Total comprehensive loss for the period | (89,821 | ) | (218,530 | ) | (32,516 | ) | ||||||
| Attributable to: | ||||||||||||
| Equity holders of the parent | (89,821 | ) | (217,973 | ) | (31,600 | ) | ||||||
| Non-controlling interest | — | (557 | ) | (916 | ) | |||||||
| Total comprehensive loss for the period | (89,821 | ) | (218,530 | ) | (32,516 | ) | ||||||
| Immatics Press Release March 23, 2022 | 8 | 10 |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Cash Flows of Immatics N.V.
| Year ended December 31, | ||||||||||||
| 2021 | 2020 | 2019 | ||||||||||
| (Euros in thousands) | ||||||||||||
| Cash flows from operating activities | ||||||||||||
| Loss before taxation | (93,335 | ) | (211,841 | ) | (32,487 | ) | ||||||
| Adjustments for: | ||||||||||||
| Interest income | (133 | ) | (850 | ) | (790 | ) | ||||||
| Depreciation and amortization | 5,260 | 4,424 | 3,858 | |||||||||
| Interest expense | 566 | 289 | 170 | |||||||||
| Share listing expense | — | 152,787 | — | |||||||||
| Equity settled share-based payment | 26,403 | 22,908 | 152 | |||||||||
| MD Anderson compensation expense | — | 45 | 700 | |||||||||
| (Decrease) Increase in other liabilities resulting from share appreciation rights | — | (2,036 | ) | 1,864 | ||||||||
| Payment related to share-based compensation awards previously classified as equity-settled | — | (4,322 | ) | — | ||||||||
| Net foreign exchange differences | 554 | (4,477 | ) | 3 | ||||||||
| Change in fair value of warrant liabilities | 10,990 | (17,775 | ) | — | ||||||||
| Changes in working capital | ||||||||||||
| Decrease (increase) in accounts receivable | 569 | (294 | ) | (563 | ) | |||||||
| (Increase) in other assets | (483 | ) | (1,600 | ) | (1,497 | ) | ||||||
| (Decrease) increase in accounts payable and other current liabilities | (31,784 | ) | (23,387 | ) | 98,937 | |||||||
| Interest received | 175 | 808 | 790 | |||||||||
| Interest paid | (566 | ) | (289 | ) | (170 | ) | ||||||
| Net cash used in operating activities | (81,784 | ) | (85,610 | ) | 70,967 | |||||||
| Cash flows from investing activities | ||||||||||||
| Payments for property, plant and equipment | (5,106 | ) | (7,420 | ) | (2,143 | ) | ||||||
| Cash paid for investments in Other financial assets | (11,298 | ) | (58,087 | ) | (77,810 | ) | ||||||
| Cash received from maturity of investments classified in Other financial assets | 24,448 | 49,662 | 74,888 | |||||||||
| Payments for intangible assets | (551 | ) | (104 | ) | (91 | ) | ||||||
| Proceeds from disposal of property, plant and equipment | — | — | 97 | |||||||||
| Net cash (used in)/provided by investing activities | 7,493 | (15,949 | ) | (5,059 | ) | |||||||
| Cash flows from financing activities | ||||||||||||
| Proceeds from issuance of shares to equity holders of the parent | 94 | 217,918 | — | |||||||||
| Transaction cost deducted from equity | — | (7,939 | ) | — | ||||||||
| Payments for leases | (2,707 | ) | (2,096 | ) | (1,862 | ) | ||||||
| Net cash used in financing activities | (2,613 | ) | 207,883 | (1,862 | ) | |||||||
| Net increase in cash and cash equivalents | (76,904 | ) | 106,324 | 64,046 | ||||||||
| Cash and cash equivalents at beginning of period | 207,530 | 103,353 | 39,367 | |||||||||
| Effects of exchange rate changes on cash and cash equivalents | 2,368 | (2,147 | ) | (60 | ) | |||||||
| Cash and cash equivalents at end of period | 132,994 | 207,530 | 103,353 | |||||||||
| Immatics Press Release March 23, 2022 | 9 | 10 |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Changes in Shareholders’ equity (deficit) of Immatics N.V.
| (Euros in thousands) | Share | Share | Accumulated | Other | Total equity (deficit)ccc | Non- | Total | |||||||||||||||||||||
| Balance as of January 1, 2019 | 1,164 | 190,793 | (201,623 | ) | (741 | ) | (10,407 | ) | 1,236 | (9,171 | ) | |||||||||||||||||
| Other comprehensive loss | — | — | — | (29 | ) | (29 | ) | — | (29 | ) | ||||||||||||||||||
| Net loss | — | — | (31,571 | ) | — | (31,571 | ) | (916 | ) | (32,487 | ) | |||||||||||||||||
| Comprehensive loss for the year | — | — | (31,571 | ) | (29 | ) | (31,600 | ) | (916 | ) | (32,516 | ) | ||||||||||||||||
| Equity-settled tandem awards | — | 152 | — | — | 152 | — | 152 | |||||||||||||||||||||
| MD Anderson compensation expense | — | — | — | — | — | 700 | 700 | |||||||||||||||||||||
| Balance as of December 31, 2019 | 1,164 | 190,945 | (233,194 | ) | (770 | ) | (41,855 | ) | 1,020 | (40,835 | ) | |||||||||||||||||
| Balance as of January 1, 2020 | 1,164 | 190,945 | (233,194 | ) | (770 | ) | (41,855 | ) | 1,020 | (40,835 | ) | |||||||||||||||||
| Other comprehensive loss | — | — | — | (6,689 | ) | (6,689 | ) | — | (6,689 | ) | ||||||||||||||||||
| Net loss | — | — | (211,284 | ) | — | (211,284 | ) | (557 | ) | (211,841 | ) | |||||||||||||||||
| Comprehensive loss for the year | — | — | (211,284 | ) | (6,689 | ) | (217,973 | ) | (557 | ) | (218,530 | ) | ||||||||||||||||
| Reorganization | (833 | ) | 833 | — | — | — | — | — | ||||||||||||||||||||
| Issue of share capital | ||||||||||||||||||||||||||||
| MD Anderson Share Exchange | 7 | 501 | — | — | 508 | (508 | ) | — | ||||||||||||||||||||
| PIPE Financing, net of transaction costs | 104 | 89,973 | — | — | 90,077 | — | 90,077 | |||||||||||||||||||||
| ARYA Merger, net of transaction costs | 180 | 237,864 | — | — | 238,044 | — | 238,044 | |||||||||||||||||||||
| SAR conversion | 7 | (7 | ) | — | — | — | — | — | ||||||||||||||||||||
| Total issuance of share capital | 298 | 328,331 | — | — | 328,629 | (508 | ) | 328,121 | ||||||||||||||||||||
| Equity-settled share-based compensation | — | 22,908 | — | — | 22,908 | — | 22,908 | |||||||||||||||||||||
| Payment related to share-based compensation awards previously classified as equity-settled | — | (4,322 | ) | — | — | (4,322 | ) | — | (4,322 | ) | ||||||||||||||||||
| MD Anderson milestone compensation expense | — | — | — | — | — | 45 | 45 | |||||||||||||||||||||
| Balance as of December 31, 2020 | 629 | 538,695 | (444,478 | ) | (7,459 | ) | 87,387 | — | 87,387 | |||||||||||||||||||
| Balance as of January 1, 2021 | 629 | 538,695 | (444,478 | ) | (7,459 | ) | 87,387 | — | 87,387 | |||||||||||||||||||
| Other comprehensive income | — | — | — | 3,514 | 3,514 | — | 3,514 | |||||||||||||||||||||
| Net loss | — | — | (93,335 | ) | — | (93,335 | ) | — | (93,335 | ) | ||||||||||||||||||
| Comprehensive income/(loss) for the year | — | — | (93,335 | ) | 3,514 | (89,821 | ) | — | (89,821 | ) | ||||||||||||||||||
| Equity-settled share-based compensation | — | 26,403 | — | — | 26,403 | — | 26,403 | |||||||||||||||||||||
| Share options exercised | — | 94 | — | — | 94 | — | 94 | |||||||||||||||||||||
| Balance as of December 31, 2021 | 629 | 565,192 | (537,813 | ) | (3,945 | ) | 24,063 | — | 24,063 | |||||||||||||||||||
| Immatics Press Release March 23, 2022 | 10 | 10 |
Exhibit 99.2
© Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation March 23, 2022 1
Forward - Looking Statements 2 This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and Immatics nor any of its affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation . You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the information contained herein to make any decision . Forward - Looking Statements . Certain statements in this presentation may be considered forward - looking statements . Forward - looking statements generally relate to future events or the Company’s future financial or operating performance . For example, statements concerning timing of data read - outs for product candidates, the clinical trial application for IMA 204 , IMA 301 , IMA 401 , the Company’s focus on partnerships to advance its strategy, projections of future cash on hand and other metrics are forward - looking statements . In some cases, you can identify forward - looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology . Such forward - looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements . These forward - looking statements are based upon estimates and assumptions that, while considered reasonable Immatics and its management, are inherently uncertain . New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties . Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”) . Nothing in this presentation should be regarded as a representation by any person that the forward - looking statements set forth herein will be achieved or that any of the contemplated results of such forward - looking statements will be achieved . You should not place undue reliance on forward - looking statements, which speak only as of the date they are made . Company undertakes no duty to update these forward - looking statements . No Offer or Solicitation . This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction . No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933 , as amended, and otherwise in accordance with applicable law . Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company’s own internal estimates and research . In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions . Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source . Clinical study results and associated biomarker studies presented within this presentation are by definition prior to completion of the clinical trial and a clinical study report and, are therefore, preliminary in nature and subject to further quality checks including customary source data verification . This meeting and any information communicated at this meeting are strictly confidential and should not be discussed outside your organization .
Building a Leading TCR Therapeutics Company 3 Intro Clinical PoC for Cell Therapy Objective responses across multiple solid tumors in early TCR - T clinical development Differentiated Approach Unique technologies to identify true cancer targets and right TCRs Strategic Partnerships World - leading industry players with synergistic expertise Solid Cash Runway To reach next value inflections points across our portfolio Therapeutic Opportunity Addressing relevant patient populations across multiple solid cancer indications Comprehensive TCR Approach Building a TCR - T Cell Therapy and TCR Bispecifics Pipeline
Our TCR - based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface 4 Intro
Two TCR - based Therapeutic Modalities 5 Distinct mechanisms of actions and therapeutic application to address the needs of a broad patient population at different stages of disease and with different types of tumors Intro
Our Pipeline of TCR - based Adoptive Cell Therapies and Bispecifics 6 1 Phase 1a: Dose escalation, Phase 1b: Dose expansion Modality Product Candidate Target Preclinical Phase 1a 1 Phase 1b 1 Phase 2/3 ACTengine® Autologous ACT IMA203 PRAME IMA203CD8 PRAME IMA201 MAGEA4/8 IMA202 MAGEA1 IMA204 COL6A3 Autologous ACT 3 programs Undisclosed 2 programs Undisclosed ACTallo® Allogeneic ACT IMA30x Undisclosed TCER® Bispecifics IMA401 MAGEA4/8 IMA402 PRAME IMA40x Undisclosed Bispecifics 3 programs Undisclosed + Checkpoint Inhibitor Intro
Maximizing Asset Potential through Strategic Collaborations Synergistic Expertise that Can Foster Transformative Innovations for ACT and Bispecifics 7 2019 2021 2020 2018 Each of our 9 partnered programs may be eligible for • >$500 million aggregated milestone payments • Tiered royalties Broadening the clinical framework beyond our proprietary pipeline Research collaboration to develop bispecific immunotherapies 3 Immatics targets $54 M upfront Co - promotion option Research collaboration to develop TCR - T therapies 3 Immatics targets $75 M upfront; Opt - in rights for BMS Co - development/Co - fund option Research collaboration to develop TCR - T therapies 2 Immatics targets $50 M upfront Co - development possibility Licensing agreement to develop Immatics’ TCR Bispecific program TCER® IMA401 $150 M upfront Co - fund/Co - promotion option in the US Intro
IMA201 / IMA401 IMA202 IMA203 / IMA402 IMA204 MAGEA4/8 MAGEA1 PRAME COL6A3 exon 6 Selected solid cancer indications with significant target prevalence 1 Sarcoma Subtypes – up to 80% Squamous NSCLC – 50% HNSCC – 35% Bladder Carcinoma – 30% Esophageal Carcinoma – 25% Uterine Carcinosarcoma – 25% Ovarian Carcinoma – 20% Melanoma – 20% HCC – 40% Squamous NSCLC – 35% Sarcoma Subtypes – up to 30% Melanoma – 30% Bladder Carcinoma – 20% Esophageal Carcinoma – 20% Uterine Carcinoma – 100% Sarcoma Subtypes – up to 100% Melanoma – 95% Uveal Melanoma – 80% 2 Ovarian Carcinoma – 80% Squamous NSCLC – 65% Kidney Carcinoma – up to 45% Cholangiocarcinoma – 35% Adeno NSCLC – 25% Breast Carcinoma – 25% HNSCC – 25% Esophageal Carcinoma – 20% HCC – 20% Bladder Carcinoma – 20% Pancreatic Carcinoma – 80% Breast Carcinoma – 75% Stomach Carcinoma – 65% Sarcoma – 65% Esophageal Carcinoma – 60% Squamous NSCLC – 55% Adeno NSCLC – 55% HNSCC – 55% Uterine Carcinosarcoma – 55% Colorectal Carcinoma – 45% Mesothelioma – 45% Cholangiocarcinoma – 40% Ovarian Carcinoma – 40% Melanoma – 35% Bladder Carcinoma – 35% Addressing Relevant Patient Populations across Multiple Solid Cancers 8 1 Solid cancer indications with 20% or more target expression, Target prevalence for selected cancer indications based on mRNA expression (TCGA and Immatics inhouse data); 2 Based on metastatic uveal melanoma patients screened in IMA203 study (N=12) Intro IMA200 & IMA400 programs demonstrate relevant expression in m ultiple s olid cancers
ACTengine® IMA203 – TCR - T Targeting PRAME 9
ACTengine® IMA203 – TCR - T Targeting PRAME Broadly Expressed Target on Multiple Solid Cancers Combined with Highly Specific TCR 10 HLA - A*02 - presented peptide derived from PRAME Naturally and specifically presented on tumors at high target density 1 : 100 - 1,000 copies/cell Identified and validated by XPRESIDENT® quant. mass spectrometry platform High - affinity, specific TCR targeting PRAME Pairing - enhanced, engineered TCR to avoid mispairing High functional avidity 2 : EC50 ~5 ng/ml Identified and characterized by XCEPTOR® TCR discovery and engineering platform TARGET TCR C LINICAL DATA N=18 pts treated in phase 1 dose escalation cohort Manageable tolerability profile; no additional DLTs 3 & no CRS/ICANS ≥ grade 3 16 patients with at least one post treatment tumor assessment Objective responses in 50% (8/16) of patients, thereof 62% (8/13) of responses above DL1; all doses still below 1 bn cells PATIENT POPULATION 4 Uterine Carcinoma – 100% Sarcoma Subtypes – up to 100% Melanoma – 95% Uveal Melanoma – 80% 5 Ovarian Carcinoma – 80% Squamous NSCLC – 65% Kidney Carcinoma – up to 45% Cholangiocarcinoma – 35% Adeno NSCLC – 25% Breast Carcinoma – 25% HNSCC – 25% Esophageal Carcinoma – 20% HCC – 20% Bladder Carcinoma – 20% Data cut - off – 05 - Oct - 2021 1 Target density: peptide copy number per tumor cell, approximate range representing the majority of tumor samples analyzed; 2 Functional avidity: EC50 half maximal effective concentration; 3 One DLT in DL2 previously reported in March 2021, fully resolved; 4 Solid cancer indications with 20% or more target expression, Target prevalence for selected cancer indications based on mRNA expression (TCGA and Immatics inhouse data); 5 Based on metastatic uveal melanoma patients screened in IMA203 study (N=12) IMA203
ACTengine® IMA203 Targeting PRAME – Mechanism of Action Immatics’ Leading TCR - T Approach 11 IMA203
Optimized Cell Therapy Products to Enhance T cell Persistence & Efficacy Current Proprietary Manufacturing P rotocol for ACTengine ® Product Candidates 12 Proprietary Manufacturing Process, designed to x reduce manufacturing process to approx. 1 week x shorten vein - to - vein time x generate younger T cells with increased proliferative capacity x improve engraftment and persistence in patients while utilizing smaller doses In - house state - of - the - art cGMP Facility 1 x Manufacturing by Immatics personnel x Maximum capacity: 48 manufacturing runs/month x Substantial in - house process development expertise 1 Exclusive access through collaboration with UT Health, Houston, TX Expedited QC testing (~1 week) Manufacturing time (~1 week) QC testing (Full sterility, 2 weeks ) Manufacturing time (~1 week) Commercial ACTengine® expected ~2 weeks ACTengine® IMA200 programs : ~3 weeks Leukapheresis Infusion - Ready A CTengine ®
ACTengine® IMA203 – Patient Flow 13 HLA - A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase ACTengine ® Manufacturing by Immatics Infusion of ACTengine® T cell Product Lymphodepletion 30 mg/m 2 Flu darabine 1 and 500 mg/m 2 Cy clophosphamide for 4 days Target Profiling Fresh Tumor Biopsy; IMADetect® Low dose IL - 2 1m IU daily days 1 - 5 and twice daily days 6 - 10 * Safety and efficacy monitoring for 12 months IMA201 IMA202 IMA203 * IL - 2 dose reduction from twice daily to daily for the first 5 days and dosing duration from 14 to 10 days introduced prior to treatment of first patients on dose level 3 ; 1 Dose reduction of Fludarabine (from 40 mg/m 2 to 30 mg/m 2 ) was introduced prior to treatment of the first patient on dose level 3 Leuka - pheresis IMA203
ACTengine® IMA203 – Key Objectives & Trial Design Presented at SITC Conference as Late - Breaking Presentation (Cut - off October 05, 2021) Trial Design & Recruitment Status 1 Enrichment cohorts EC1 & EC2: patients infused with intermediate doses enabling infusion of patients with medical need during do se escalation observation periods, or in case of lower production yields; * One patient infused at the same dose level as part of the enrichment cohort; ** Dose is shown as transduced viable CD8 T cells per m 2 total body surface area Key Study Objectives • Primary: Safety Investigation of Adverse Events, Determination of a recommended Phase 2 dose • Secondary: Biological and Clinical Activity T cell engraftment and persistence Objective responses as per RECIST1.1 Duration of response • Exploratory Tumor Infiltration 14 Data cut - off – 05 - Oct - 2021 18 patients 1 infused with PRAME - directed T cells at 5 clinical sites N=3 ** N=3 Ongoing N=1 N=4 patients treated at intermediate dose levels 1 N=7 * IMA203
ACTengine® IMA203 – Safety Profile Manageable & Transient Treatment - emergent Adverse Event s – No ≥ Grade 3 CRS or ICANS Adverse event All grades ≥ Grade 3 No . % No . % Patients with any adverse event 19 100.0 19 100.0 Adverse Events of Special interest Cytokine release syndrome 1 7 8 9.5 0 0.0 ICANS 2 4 21.1 0 0.0 Blood and lymphatic system disorders Neutropenia* 16 84.2 15 78.9 Anaemia 1 6 84.2 9 47.4 Thrombocytopenia 15 78.9 7 36.8 Lymphopenia* 14 73.7 14 73.7 Leukopenia* 12 63.2 1 1 57.9 Cytopenia 1 5.3 1 5.3 Infections and infestations Enterococcal infection 1 5.3 1 5.3 COVID - 19 1 5.3 1 5.3 Appendicitis 1 5.3 1 5.3 Sepsis 3 1 5.3 1 5.3 Respiratory, thoracic and mediastinal disorders Hypoxia 2 10.5 1 5.3 Pleural effusion 2 10.5 1 5.3 Bronchial obstruction 1 5.3 1 5.3 Metabolism and nutrition disorders Hyponatraemia 7 36.8 1 5.3 Hypokalaemia 5 26.3 1 5.3 Decreased appetite 3 15.8 0 0.0 Adverse event All grades ≥ Grade 3 No . % No . % table continued… Cardiac or vascular disorders Hypertension 3 15.8 2 10.5 Atrial fibrillation 2 10.5 1 4 5.3 General disorders and administration site conditions Fatigue 7 36.8 1 5.3 Pyrexia 5 26.3 0 0.0 Oedema peripheral 3 15.8 0 0.0 Gastrointestinal disorders Nausea 12 63.2 0 0.0 Vomiting 7 36.8 0 0.0 Diarrhoea 7 36.8 0 0.0 Constipation 6 31.6 0 0.0 Investigations Aspartate aminotransferase increased 5 26.3 0 0.0 Alanine aminotransferase increased 4 21.1 0 0.0 Blood creatinine increased 4 21.1 0 0.0 Other Rash 5 26.3 0 0.0 Myalgia 4 21.1 0 0.0 Arthralgia 3 15.8 0 0.0 Alopecia 3 15.8 0 0.0 Rash maculo - papular 2 10.5 1 5.3 Orchitis 1 5.3 1 5.3 Contrast media allergy 1 5.3 1 5.3 TEAEs by maximum severity ( N=19) 1 1 All treatment - emergent adverse events (TEAEs) with grade 1 - 2 occurring in at least 3 patients (incidence ≥ 15 . 8 % ) and additionally all events with grade 3 - 5 regardless of relatedness to study treatment are presented . Data source : clinical database . Adverse events were coded using the Medical Dictionary for Regulatory Activities . Grades were determined according to National Cancer Institute Common Terminology Criteria of Adverse Events (CTCAE), version 5 . 0 . Grades for Cytokine release syndrome and ICANS were determined according to CARTOX criteria ( Neelapu et al . , 2018 ) . Patients are counted only once per adverse event and severity classification ; 2 ICANS : Immune effector cell - associated neurotoxicity syndrome ; 3 Patient died from sepsis of unknown origin and did not receive IMA 203 T cells ; 4 DLT : Dose limiting toxicity ; * 100 % of patients experienced transient cytopenias ≥ Grade 3 (CTCAE v 5 . 0 ) DLT: Transient, Grade 3 atrial fibrillation Onset on day 5 post infusion that resolved within 48h DLT triggered expansion of DL2 CRS/ICANS: No ≥ Grade 3 CRS or ICANS observed so far Most Adverse Events were associated with lymphodepletion 15 Data cut - off – 05 - Oct - 2021 IMA203
ACTengine ® IMA203 – Change in Target Lesions Objective Responses across Multiple Tumor Types at Doses below 1 billion Transduced Cells 1 RECIST1.1 response at the timepoint of maximum change of target lesions (week 12): PD due to new lesions ( leptomeningeal disease) at week 12 2 Patients dosed with DL2, EC1 and EC2; * Confirmed at subsequent scan; ** Confirmation pending as of data cut - off Preliminary Objective Response Rates (RECIST1.1., confirmed and unconfirmed) All doses Dosed above DL1 All comers 8/16 (50%) 8/13 (62%) Melanoma 3/3 (100%) 3/3 (100%) Head & Neck Cancer 1/3 (33%) 1/1 (100%) Synovial Sarcoma 3/5 (60%) 3/5 (60%) Uveal Melanoma 1/2 (50%) 1/2 (50%) 16 Best Overall Response (RECIST1.1) 2 0 3 - E C 2 - 0 1 2 0 3 - D L 2 - 0 2 2 0 3 - E C 1 - 0 3 2 0 3 - D L 3 - 0 3 2 0 3 - D L 2 - 0 6 2 0 3 - D L 1 - 0 3 2 0 3 - D L 1 - 0 1 2 0 3 - D L 1 - 0 2 2 0 3 - D L 2 - 0 4 2 0 3 - D L 3 - 0 2 2 0 3 - D L 2 - 0 1 2 0 3 - E C 1 - 0 2 2 0 3 - E C 1 - 0 1 2 0 3 - D L 2 - 0 5 2 0 3 - D L 2 - 0 3 2 0 3 - D L 3 - 0 1 -50 0 50 -63.3 -61.0 -51.7 -50.5 -47.7 -39.9 -37.9 -33.8 -13.1 -9.7 -6.9 -4.2 -2.0 -0.5 5.2 8.8 B e s t c h a n g e i n s u m o f d i a m e t e r [ % ] a n d B O R ( R E C I S T 1 . 1 ) Dose Level: DL2 2 DL1 DL3 PD SD SD SD SD SD SD PR* PR* PR PR PR PR PR PR* + + S C C S y n o v i a l S a r c o m a U v e a l M e l a n o m a N S C L C O v a r i a n C a n c e r H e a d & N e c k C a n c e r H e a d & N e c k C a n c e r S y n o v i a l S a r c o m a M e l a n o m a S y n o v i a l S a r c o m a S y n o v i a l S a r c o m a U v e a l M e l a n o m a M e l a n o m a M e l a n o m a 1 H e a d & N e c k C a n c e r S y n o v i a l S a r c o m a SD ** Data cut - off – 05 - Oct - 2021 IMA203
Patient ID Indication Dose 203 - DL1 - 01 Head & Neck Cancer DL1 203 - DL1 - 02 Head & Neck Cancer DL1 203 - DL1 - 03 Ovarian Cancer DL1 203 - EC1 - 01 Melanoma EC1 203 - EC1 - 02 Melanoma EC1 203 - EC1 - 03 Uveal Melanoma EC1 203 - DL2 - 01 Synovial Sarcoma DL2 203 - DL2 - 02 Synovial Sarcoma DL2 203 - DL2 - 03 Synovial Sarcoma DL2 203 - DL2 - 04 Synovial Sarcoma DL2 203 - DL2 - 05 Head & Neck Cancer DL2 203 - DL2 - 06 NSCLC DL2 203 - EC2 - 01 SCC EC2 203 - DL3 - 01 Uveal Melanoma DL3 203 - DL3 - 02 Melanoma DL3 203 - DL3 - 03 Synovial Sarcoma DL3 ACTengine ® IMA203 – Response Over Time Objective Responses across Multiple Tumor Types at Doses below 1 billion Transduced Cells x x x x x Alive (time from infusion to data cut - off or death) PD Deceased x x SD PR Week Month x x x x 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 x PR ongoing at data cut - off According to RECIST1.1 First tumor response assessment x Data cut - off – 05 - Oct - 2021 17 IMA203
ACTengine® IMA203 – Engraftment, Persistence & Tumor Infiltration Clinical Responses Consistent with Biological Data T cell Engraftment & Persistence Tumor Infiltration post I nfusion 2 1 Mann - Whitney U test, p=0.065 ; 2 Post infusion biopsies at week 6 (except one patient with SD at week 3); 3 Mann - Whitney U test, p=0.0159 2 4 1×10 -1 1×10 0 1×10 1 1×10 2 1×10 3 1×10 4 1×10 5 1×10 6 1×10 7 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 2 5 0 4 0 0 5 5 0 7 0 0 V e c t o r c o p i e s / μ g g D N A PD SD PR B a s e l i n e Days post-infusion SD PR 1×10 1 1×10 2 1×10 3 1×10 4 1×10 5 V e c t o r c o p i e s / g g D N A 0.0159 Case study High T cell engraftment and persistence with trend for association of peak vector copies with clinical response 1 High T cell infiltration observed through serial biopsies associated with clinical response 3 Data cut - off – 05 - Oct - 2021 18 p=0.0159 IMA203
ACTengine ® IMA203 – Case Study Patient IMA203 - DL3 - 01 Confirmed Partial Response with Deepening Tumor Regression in Multiple Lesions Liver metastasis Lung metastasis Sub cut . metastasis 0 5 10 15 -100 -50 0 50 Weeks from T Cell Infusion C h a n g e i n D i a m e t e r f r o m B a s e l i n e [ % ] SUM T1: Lymph Node T2: Lymph Node T3: Lung T4: Liver T5: Liver * C hange in Target Lesions T cell Persistence & Peak Response in the Blood • 62 - year - old female; m etastatic uveal melanoma • High tumor burden in multiple organs • Infused at refractory disease after failing 4 prior lines of therapy including 2 lines of CPI 1 • Patient received total dose of 0.59 billion transduced T cells following lymphodepletion • T cell persistence until end of observation & detection in the tumor • All lesions decreased at week 6 - 40% decrease in target lesions response deepened at week 12 to 63% decrease • Best Response (RECIST1.1): PR (confirmed & ongoing) Baseline Week 12 2 4 1×10 -1 1×10 0 1×10 1 1×10 2 1×10 3 1×10 4 1×10 5 1×10 6 1×10 7 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 2 5 0 5 0 0 V e c t o r c o p i e s / μ g g D N A B a s e l i n e Days post-infusion IMA203 1 Immune checkpoint inhibitor Data cut - off – 05 - Oct - 2021 19
Preliminary Findings after Completion of Dose Level 3 ACTengine® IMA203 PRAME – Phase 1a Dose Escalation Interim Update 1 DLT: dose - limiting toxicity, since March 17, 2021 (reported DLT at DL2); 2 CRS: cytokine release syndrome, I CANS: Immune effector cell - associated neurotoxicity syndrome, both graded by CARTOX criteria ( Neelapu et al ., 2018); 3 Objective response rate according to RECIST 1.1 including confirmed and unconfirmed partial responses; * Includes patients treated at enrichment cohorts EC1 and EC2 Additional DLTs 1 ORR 3 at DL2 * & DL3 (8/13 patients) – all still dosed below 1 bn cells SAFETY CLINICAL ACTIVITY BIOLOGICAL ACTIVITY 3 0 Dose levels completed, all below 1 bn cells 0 Grade ≥3 CRS or ICANS 2 50% 62% ORR 3 across all doses and multiple solid cancers (8/16 patients) Blood Tumor High T cell engraftment and persistence High T cell infiltration associated with clinical response 20 Data cut - off – 05 - Oct - 2021 IMA203 Objective responses observed across multiple tumor types at dose levels below 1 billion T cells originally presumed to be subtherapeutic
Our Plans to Achieve Long - Lasting Responses with TCR - T cells against PRAME Phase 1b Cohort A: IMA203 Target Dose in Focus Indications Phase 1b Cohort B: IMA203/Checkpoint Inhibitor Combination Therapy Phase 1b Cohort C: IMA203CD8 2nd Gen Monotherapy Phase 1a: IMA203 Monotherapy Dose Escalation in Basket Trial Target Cell Dose, Therapeutic Combination & Next - generation Engineering Patient treatment in Ph1a completed & provisional RP2D 1 determined early 2022 Ph1b Expansion starting 2022 Ph2b Pivotal Trial(s) 21 1 2 3 E ach expansion cohort is designed to evaluate the observed objective response rate, demonstrate durability of response & provide the basis for entering registration trials 21 Enrollment starting in Q2 Enrolling patients Enrollment planned for Q2 Building on Initial Success Harness Synergies CPI/TCR - T Empowering CD4 T cells 2 IMA203 1 Exploration of higher dose (DL5) planned; 2 Demonstrated to be important for long term remission: M elenhorst et al. 2022 Nature
ACTengine® IMA203CD8 – Next - generation TCR - T Building on First - Gen IMA203 Success to Further Improve Anti - Tumor Activity • Engagement of CD4 T cells by CD8 co - transduction reported to boost anti - tumor activity in TCR - T trials • Recent data from leukaemia patients treated with CAR - T achieving decade - long remissions show that CD4 T cells d ominat e at the later t ime p oints of response 1 • Functional superiority of the CD8 αβ construct over multiple other CD8 constructs in preclinical experiments • Proprietary 4 - in - 1 lentiviral vector to engineer CD4 and CD8 T cells with the PRAME - specific IMA203 TCR and CD8 αβ construct (IMA203CD8) IND filing for IMA203CD8 lead candidate targeted in 1H 2022 TUMOR CELL DEATH CD4 T CELL Cytotoxi c Activity CD8 T CELL T cell Help Cytotoxi c Activity 22 IMA203CD8 1 Melenhorst et al. 2022 Nature
ACTengine® IMA203CD8 – Preclinical Assessment of Anti - Tumor Efficacy Co - Transduction of CD8 Enhances Anti - Tumor Activity in Vitro 18 36 56 74 94 114134 152 172192 0.0 0.5 1.0 1.5 2.0 IMA203CD8 TCR IMA203 TCR Non - Transduced Control S erial Killing Assay – CD8 & CD4 T cells Engagement of CD4 T cells may enhance depth and durability of anti - tumor response and clinical outcome of TCR - T in solid cancer patients 2 nd addition of tumor cells 3 rd addition of tumor cells Tumor Growth Hours after co - culture F ull Data Presentation at SITC 2021: Improved anti - tumor activity of next - generation TCR - engineered T cells through CD8 co - expressio n Day 0 D ay 3 N o CD4 T cells IMA203 TCR D ay 6 IMA203CD8 TCR 3D Spheroid Killing – CD4 T cells 23 IMA203CD8
ACTengine® IMA201 Targeting MAGEA4/8 Key Features 24 HLA - A*02 - presented peptide derived from MAGEA4 and/or MAGEA/8 >5 - fold higher peptide copy number per tumor cell than a commonly used MAGEA4 target Naturally and specifically presented on tumors at high target density 1 : 100 - 1,000 copies/cell Identified and validated by XPRESIDENT® quant. mass spectrometry platform High - affinity, specific TCR targeting MAGE4/8 High functional avidity 2 : EC50 ~10 ng/ml Identified and characterized by XCEPTOR® TCR discovery and engineering platform N=2 pts treated in phase 1 dose escalation cohort DL2 commenced Too early for assessment of safety or anti - tumor activity Sarcoma Subtypes – up to 80% Squamous NSCLC – 50% HNSCC – 35% Bladder Carcinoma – 30% Esophageal Carcinoma – 25% Uterine Carcinosarcoma – 25% Ovarian Carcinoma – 20% Melanoma – 20% Data cut - off – 17 - Sep - 2021 1 Target density: peptide copy number per tumor cell, approximate range representing the majority of tumor samples analyzed; 2 Functional avidity: EC50 half maximal effective concentration; 3 Solid cancer indications with 20% or more target expression, Target prevalence for selected cancer indications based on mRNA expression (TCGA and Immatics inhouse data) TARGET TCR C LINICAL DATA PATIENT POPULATION 3 IMA201
ACTengine® IMA202 Targeting MAGEA1 Key Features 25 HLA - A*02 - presented peptide derived from MAGEA1 Naturally and specifically presented on tumors at high target density 1 : 50 - 900 copies/cell Identified and validated by XPRESIDENT® quant. mass spectrometry platform High - affinity, specific TCR targeting MAGE1 High functional avidity 2 : EC50 ~15 ng/ml Identified and characterized by XCEPTOR® TCR discovery and engineering platform N=10 pts treated in phase 1 dose escalation cohort Target dose level DL3 ongoing Manageable tolerability profile; no DLTs or CRS/ICANS ≥ grade 3 Disease control in 7/10 patients (9 pts in DL1 & DL2) Maximum change of target lesion - 35.4% in melanoma pt 3 HCC – 40% Squamous NSCLC – 35% Sarcoma Subtypes – up to 30% Melanoma – 30% Bladder Carcinoma – 20% Esophageal Carcinoma – 20% Data cut - off – 17 - Sep - 2021 1 Target density: peptide copy number per tumor cell, approximate range representing the majority of tumor samples analyzed; 2 Functional avidity: EC50 half maximal effective concentration; 3 Timepoint of maximum change of target lesion (week 12): PD due to growth of non - target lesion; 4 Solid cancer indications with 20% or more target expression, Target prevalence for selected cancer indications based on mRNA expression (TCGA and Immatics inhouse data) TARGET TCR C LINICAL DATA PATIENT POPULATION 4 IMA202
ACTengine® IMA204 First - in - Class TCR - T Targeting Tumor Stroma Key Features 26 HLA - A*02 - presented peptide derived from COL6A3 exon 6 Naturally and specifically presented on tumors at high target density 1 : 100 - 700 copies/cell Novel tumor stroma target identified and validated by XPRESIDENT® quant. mass spectrometry platform High - affinity, specific TCR targeting COL6A3 exon 6 Affinity - maturated, CD8 - independent TCR High functional avidity 2 : ~0.01ng/ml Identified and characterized by XCEPTOR® TCR discovery and engineering platform CD8 - independent, next - generation TCR engages both, CD8 and CD4 T cells In vitro anti - tumor activity against target - positive cell lines in CD8 and CD4 T cells Complete tumor eradication in in vivo mouse models Pancreatic Carcinoma – 80% Breast Carcinoma – 75% Stomach Carcinoma – 65% Sarcoma – 65% Esophageal Carcinoma – 60% Squamous NSCLC – 55% Adeno NSCLC – 55% HNSCC – 55% Uterine Carcinosarcoma – 55% Colorectal Carcinoma – 45% Mesothelioma – 45% Cholangiocarcinoma – 40% Ovarian Carcinoma – 40% Melanoma – 35% Bladder Carcinoma – 35% 1 Target density: peptide copy number per tumor cell, approximate range representing the majority of tumor samples analyzed; 2 Functional avidity: EC50 half maximal effective concentration; 3 Solid cancer indications with 20% or more target expression, Target prevalence for selected cancer indications based on mRNA expression (TCGA and Immatics inhouse data) TARGET TCR PREC LINICAL DATA PATIENT POPULATION 3 IMA204 provides a promising therapeutic opportunity for a broad patient population as monotherapy or in combination with TCR - T cells directed against tumor targets IMA204
ACTengine® IMA204 – High Affinity, CD8 - independent TCR Complete Tumor Eradication in vitro & in vivo 1 by Affinity - enhanced IMA204 TCR CD8 - independent TCR leads to tumor eradication in all mice treated Control IMA204 TCR D7 D16 D22 D29 27 • Affinity maturated CD8 - independent, next - generation TCR engages both CD4 and CD8 T cells without the need of CD8 co - transduction • IND - enabling studies are nearing completion Stroma cells Tumor cells Stroma Target (COL6A3 exon 6) in Ovarian Cancer sample Example of a Tumor Target in same Ovarian Cancer sample 1 In vivo data in collaboration with Jim Riley, University of Pennsylvania, control: non - transduced T cells. TCR avidity and specificity d ata not shown, available in IMA204 presentation on Immatics website. COL6A3 exon 6 prevalently expressed at high target density in tumor stroma across many solid cancers IMA204
ACTallo® IMA30X – Immatics’ Allogeneic Cell Therapy Approach Effective Redirection of γδ T cells Using αβ TCR 28 • Proprietary manufacturing protocol delivering robust expansion of γδ T cells with the potential for hundreds of doses from one single donor leukapheresis • Off - the - shelf cell therapy , applicable without need for personalized manufacturing and not reliant on potentially encumbered immune system of patient • High potency: TCR transduced γδ T cells show similar anti - tumor activity to αβ T cells • Proprietary single lentiviral vector system (4 - in - 1 construct) including TCR and CD8 alpha & beta chains • γδ T cells are abundant, show intrinsic anti - tumor activity, naturally infiltrate solid tumors and do not cause graft - vs - host disease γδ T cell collection from healthy donor Off - the - shelf product Transduction Expansion ACTallo ® Immatics’ Allogeneic ACT Approach ACTallo®
TCER® – TCR Bispecifics 29
TCER® – Mechanism of Action Immatics’ Off - the - Shelf TCR Bispecifics Approach 30 TCER®
TCER® – Immatics’ Half - Life Extended Bispecifics 31 pHLA targeting TCR x High - affinity TCR targeting HLA - restricted tumor - specific peptides x Broad therapeutic window through XPRESIDENT® - guided affinity maturation (>1000x) 2 x Complete tumor eradication in mouse xenograft models at low doses T cell recruiting antibody x Low - affinity T cell recruiter against both TCR & CD3 x Optimized biodistribution aiming for enrichment at tumor site and prevention of CRS 1 x Superior anti - tumor activity in mouse models as compared to widely used CD3 recruiters Next - generation TCER® format x Off - the - shelf b iologic with antibody - like manufacturability 3 and low cost of goods x Superior anti - tumor activity 4 compared to six alternative bispecific formats x Half - life of several days expected in humans TCER® T cell recruiting antibody pHLA targeting TCR Fc domain (silenced) with KiH technology Our TCER® format is designed to maximize efficacy while minimizing toxicities in patients 1 Based on literature data for other low - affinity recruiters (e.g. Harber et al ., 2021, Nature); 2 As compared to natural TCR; 3 Production in mammalian cells (CHO cells); 4 Based on preclinical testing TCER®
TCER® – Development of a Proprietary TCR Bispecific Format Flexible Plug - and - play Platform Designed to Efficiently Generate New TCR Bispecifics 32 • Immatics developed a proprietary TCR Bispecific format for specific targeting of tumor - specific pHLA at low copy numbers • TCER® format successfully validated for different TCRs and different T cell recruiting antibodies Fc - domain (silenced IgG1, heterodimerization via KiH S - S ) anti - pHLA TCR high affinity T cell - recruiting Ab low affinity NH 2 NH 2 COOH COOH C H 3 C H 2 Hinge CH3 KiH VL V β VH V α TCER®
Potency of Our Proprietary TCR Bispecific Format TCER® 33 • Seven different TCR Bispecific formats were evaluated with a pHLA targeting TCR and the identical T cell recruiting antibody • TCER® format had higher combination of potency and specificity 1 than six alternative TCR Bispecific format designs evaluated TCER® TCER® 2+1 TCR bispecific format: High potency was linked to a significantly reduced specificity profile Killing of target - positive cells by different TCR Bispecifics 1 Preclinical data on specificty not shown
TCER® Portfolio Building a Pipeline of Next - Gen Half - Life Extended TCR Bispecifics 34 IMA401 IMA402 IMA40X MAGEA4/8 PRAME Undisclosed Status CTA 1 approved in February 2022; Start of Phase 1 trial in 2Q 2022 Clinical GMP batch targeted in 2022 Phase 1 trial in 2023 TCER ® engineering and preclinical testing ongoing Preclincial Proof - of - concept – Efficacy / Safety » Complete remission of estab . tumors in xenograft mouse models at low doses » Very broad therapeutic window (reactivity tumor compared to normal cells) n/a Half - life Half - life extended to several days via effector function silenced Fc part Clinical Development Strategy » First - in - human basket trial » Adaptive design aiming at fast dose escalation » Development strategy includes TCER ® as add on to checkpoint inhibitor - based standard of care in early lines of treatment TCER® 1 Clinical trial application – the European equivalent of an Investigational New Drug (IND) application
TCER® IMA401 Targeting MAGEA4/8 IND - stage Product Candidate in Development with Bristol Myers Squibb 35 Treatment schedule Tumor Model in Mice 1 1 8 15 22 Study day Transplantation Human PBMC IMA401 TCER ® Transplantation Tumor -22-12 • Complete remissions observed in all animals even at low IMA401 dose of 0.05 mg/kg • No detectable outgrowth of tumors during prolonged observation period of 70 days N=6 mice per group, two PBMC donors Dose: two dose levels TCER® 1 Hs695T xenograft model in MHC I/II ko NSG mice, tumor volume of individual mice shown
TCER ® IMA402 Targeting PRAME Preclinical - stage Product Candidate Fully Owned by Immatics PRAME Target Peptide • HLA - A*02 - restricted PRAME peptide targeted by TCER® IMA402 is one of the most frequently expressed intracellular cancer targets for TCR - based therapies » Homogenously expressed at high prevalence across multiple solid tumors including melanoma, lung cancer, gynecological cancers (ovarian, breast, uterine) and others Preclinical Proof - of - Concept Data • High in vitro potency in killing of tumor cells with physiological PRAME peptide levels • Favorable safety profile with broad therapeutic window between tumor and normal cell reactivity in vitro • Consistent tumor regression including complete responses in NOG mice treated at low doses • Extended serum half - life of several days 1 expected in humans driven by the TCER® Fc part Well Progressing CMC Development • Current data support antibody - like manufacturability and developability • GMP process development and IND - enabling activities ongoing • Manufacturing of the clinical batch for the Phase 1 trial expected in 2H 2022 36 1 Based on preclinical testing TCER®
TCER® IMA402 – Efficacy Assessment in Tumor Model in Mice Superior Tumor Control Using a Proprietary, Low - Affinity Recruiter 37 Widely used T cell recruiting Ab (3 variants) medium to high affinity Treatment schedule N=6 mice per group, two PBMC donors Dose: 0.025 mg/kg Proprietary, low - affinity T cell recruiting region demonstrates superior tumor control compared to analogous TCER® molecules designed with higher - affinity variants of a widely used recruiter Immatics’ T cell recruiting Ab low affinity IMA402 Treatment start Administration of IMA402 in defined dosage interval TCER® Tumor Model in Mice 1 1 Hs695T xenograft model in NOG m ice , tumor volume of group means shown Bunk at al ; PEGS2021
TCER® IMA402 – In vitro Safety Assessment with Normal Tissue Cells 38 • Cytotoxicity against N≥9 different human normal tissue cell types • TCER® IMA402 shows a minimum of 1,000 - fold therapeutic window between normal tissue cell reactivity and tumor cell reactivity Normal Tissue Type Therapeutic Window (x - fold) IPSC - derived astrocytes ≥1 , 000 IPSC - derived GABA neurons ≥1 , 000 IPSC - derived cardiomyocytes ≥1 , 000 Human Pulmonary Fibroblasts ≥1 , 000 Human Cardiac Microvascular Endothelial Cells ≥1 , 000 Human Dermal Microvascular Endothelial Cells ≥1 , 000 Human Aortic Endothelial Cells ≥1 , 000 Human Coronary Artery Smooth Muscle Cells ≥1 , 000 Human Tracheal Smooth Muscle Cells ≥1 , 000 IPSC - derived Cardiomyocytes 0 50 100 150 10 -1 10 0 10 1 10 2 10 3 10 4 10 5 iAstrocytes and Hs695T TCER [pM] C y t o t o x i c i t y [ % ] w/o PRAME - positive tumor cell line normal tissue cell type TCER®
Immatics’ Proprietary Target and TCR Discovery Platforms 39
True Cancer Targets & Matching Right TCRs Goal to Maximize Anti - Tumor Activity and Minimize Safety Risks of TCR - based Immunotherapies 40 True Targets via XPRESIDENT® technology platform • are naturally presented on tumor tissues as identified by mass - spec • are absent or presented at only low levels on normal tissues • are presented at high copy numbers to trigger a pharmacological response + Technology Right TCRs via XCEPTOR® technology platform • recognize the target peptide with high affinity and specificity • show selective killing of tumor cells • are developed to be suitable for two different therapeutic modalities, Cell Therapies and TCR Bispecifics
Immatics ’ Unique Capability – Identification of the most Relevant Target Example of MAGEA4/8 Peptide Target 41 1 Copy number per tumor cell (CpC) measured on a paired - sample basis by AbsQuant®, i.e. comparing MAGEA4 vs. MAGEA4/A8 peptide pre sentation on same sample, 2 Students paired T test p<0.001 2 Technology MAGEA4/8 target is presented at >5 - fold higher target density 1 than a commonly used MAGEA4 target peptide XPRESIDENT® quantitative information on target density 1 between peptides originating from the same source protein Ranking of pHLA targets
Technology Pool of 200 Prioritized Targets as Foundation for Future Value Generation 42 200 Prioritized Targets Grouped in 3 Target Classes: 1. Well known and characterized parent protein (20%) e.g. MAGE family cancer testis antigens 2. Unknown or poorly characterized parent protein (60%) e.g. stroma target COL6A3 exon 6 3. Crypto - targets/Neoantigens (20%) Novel target class which includes RNA - edited peptides & non - classical neoantigens ~50% of our prioritized targets are non - HLA - A*02 restricted, substantially broadening the potential patient reach >2,500 cancer & normal tissues a nalyzed by Quantitative, Ultra - Sensitive Mass Spectrometry pHLA Database based on primary tissues >200 prioritized targets
Development of the Right TCR – XCEPTOR® Technology TCR Discovery and Engineering for ACT and TCR Bispecifics 43 TCR Bispecifics T cell engaging receptor (TCER®) Adoptive Cell Therapy ACTengine® ACTallo ® • Fast, efficient and highly sensitive discovery of highly specific, natural TCRs • Protein engineering capabilities to design and maturate TCRs with increased affinity while retaining specificity • Early de - selection of cross - reactive TCRs by the u nique interplay between Immatics’ target and TCR discovery platforms XPRESIDENT® and XCEPTOR® during TCR discovery 1 and TCR maturation 2 Micromolar affinity Nanomolar affinity Technology 1 XPRESIDENT® - guided off - target toxicity screening; 2 XPRESIDENT® - guided similar peptide counterselection
Optimal Target Selection & TCR Specificity for Minimizing Safety Risks Unique Interplay between Technology Platforms Allows Early De - risking for Clinical Development 44 Target peptide presented on tumor cells Selective killing of tumor cells Target peptide presented on normal cells Off - target toxicity On - target (off - tumor) toxicity A different HLA is recognized on normal cells Alloreactivity Similar peptide presented on normal cells 1 XPRESIDENT® - guided screening for on - and off - target toxicities of TCRs based on the extensive database of peptides presented on normal tissues Technology 1 Clinical fatalities have occurred in TCR - T trials using a titin cross - reactive TCR (Cameron et al ., Sci Transl Med)
Corporate Information & Milestones 45
Experienced Global Leadership Team Across Europe and the US 46 Harpreet Singh Chief Executive Officer Co - Founder >20 yrs biotech experience Carsten Reinhardt Chief Development Officer >20 yrs pharma & biotech experience ( Micromet , Roche, Fresenius) Rainer Kramer Chief Business Officer 25 yrs pharma & biotech experience (Amgen, MorphoSys , Jerini , Shire, Signature Dx) Steffen Walter Chief Technology Officer Co - Founder Immatics US >15 yrs biotech experience Arnd Christ Chief Financial Officer >20 yrs biotech experience ( Probiodrug , NovImmune , Medigene , InflaRx ) Toni Weinschenk Chief Innovation Officer Co - Founder >15 yrs biotech experience Jordan Silverstein Head of Strategy >10 yrs biotech experience (Advanced Accelerator Applications, InflaRx ) Edward Sturchio General Counsel >15 yrs pharma & biotech experience (Schering, Merck, Novartis, Advanced Accelerator Applications, Abeona Therapeutics) Cedrik Britten Chief Medical Officer >10 yrs pharma & biotech experience ( BioNTech , GSK) Corporate
Strong, Focused and Highly Integrated Trans - Atlantic Organization 47 Senior Leadership, Business Development, Clinical Operations, Intellectual Property, Regulatory Affairs, Communications Senior Leadership, Research and Development (Adoptive Cell Therapy), CMC, Clinical Operations, Regulatory Affairs, QA/QC, HR, Investor Relations Munich, Germany, ~45 FTEs Tübingen, Germany, ~175 FTEs Houston, Texas , ~ 125 FTEs Senior Leadership, Research and Development (XPRESIDENT®, XCEPTOR®, TCER®), Translational Development, Clinical Operations, Finance, HR, IT, QM Corporate FTE status as of 31 December 2021
Robust IP Portfolio Immatics’ Patent Estate – Territorial Coverage 48 Cancer targets, TCRs and technology protected by: • 5,800 applications and patents filed in all major countries and regions • >120 patent families • >2,000 granted patents, thereof >480 granted patents in the US Corporate
Near - Term Value Drivers and Development Milestones Clinical Expansion of TCR Bispecifics and the Next - generation of TCR - T 49 Leverage full potential of targeting PRAME • Focused & accelerated development of IMA203 expansion cohorts • Develop IMA402, an off - the - shelf TCER® Advance clinical development of ACTengine® candidates • Initiation of multiple IMA203 Ph1b expansion cohorts ongoing: Monotherapy, checkpoint combination, 2nd - gen approach IMA203CD8 • Next IMA203 monotherapy data read - out in 2H 2022 • Initial data read - out for checkpoint combination, IMA203CD8 YE 2022 • Advance IMA204 to the clinic, submission of IND application YE 2022 Move TCER® into clinical development • Trial initiation for IMA401 (MAGEA4/8) in 2Q 2022 • Manufacturing of IMA402 clinical batch in 2H 2022, clinical trial in 2023 • Innovative TCER® program(s) IMA40X in preclinical development Corporate
www.immatics.com Thank you!